A reinforcement learning model developed to adapt artificial intelligence (AI) predictions to human preferences showed better sensitivity for skin cancer diagnoses and improved management decisions compared to a supervised learning model.

In a short-term study in which hearts from gene-edited pigs were transplanted into two recently deceased human recipients, the hearts were able to function for the duration of the study without signs of rejection and without evidence of pig virus transmission, encouraging further clinical study of cardiac xenotransplantation.

Trastuzumab deruxtecan, an anti-HER2–drug conjugate, exhibits the highest objective response rate in patients with HER2-overexpressing metastatic breast cancer, but clinical activity is also observed in patients with HER2-low or non-expressing tumors, potentially pointing to additional determinants of drug efficacy.

Based on a newly developed deep-learning model for predicting the binding affinities of protein–protein interactions, the effects of SARS-CoV-2 spike protein variants on binding to the ACE2 receptor and neutralizing antibodies were analyzed and used to predict immune escape and viral evolution.

In the randomized, double-blind, phase 3 GLOW trial, capecitabine and oxaliplatin combined with zolbetuximab, a monoclonal antibody that targets CLDN18.2, significantly improved progression-free survival and overall survival in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

T cells containing an anti-mesothelin single-domain antibody fused to a component of the endogenous T cell receptor signaling complex exhibit notable toxicities but encouraging clinical responses in patients with treatment-refractory mesothelioma and ovarian cancer.

A reinforcement learning model developed to adapt artificial intelligence (AI) predictions to human preferences showed better sensitivity for skin cancer diagnoses and improved management decisions compared to a supervised learning model.

Trastuzumab deruxtecan, an anti-HER2–drug conjugate, exhibits the highest objective response rate in patients with HER2-overexpressing metastatic breast cancer, but clinical activity is also observed in patients with HER2-low or non-expressing tumors, potentially pointing to additional determinants of drug efficacy.

Treatment of patients with HER2-mutant non-small-cell lung cancer with the pan-HER inhibitor pyrotinib in a phase 2 trial or compassionate use showed a favorable objective response rate, whereas patients treated in parallel by physician’s choice in a real-world study did not.

A systematic review uncovers almost no risk for sexual transmission of HIV at low levels of viral load.

The reignited Cancer Moonshot must support science that will tackle health and economic impacts of cancer and promote health equity in low- and middle-income countries.

A new framework systematically identifies patients with ataxia telangiectasia who are amenable to splice-switching ASO therapy — and could be applied to other rare diseases.

The monoclonal antibody donanemab, which clears amyloid plaques in the brain, slowed clinical progression of early symptomatic Alzheimer’s disease.